Clinical Trials Browser

Phase 3 × INDUSTRY × dabrafenib × Clear all

NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Phase 3 Active not recruiting

153 enrolled 15 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT01682083 2026-04-21

COMBI-AD

Phase 3 Completed

870 enrolled 15 charts 1 FDA

Melanoma, Neoplasms

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT03551626 2025-04-29

COMBI-APlus

Phase 3 Completed

552 enrolled 12 charts

Fever, Melanoma

NCT01597908 2021-02-24

COMBI-v

Phase 3 Completed

704 enrolled 13 charts

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Melanoma

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Phase 3 Completed

251 enrolled 21 charts

Melanoma, Neoplasms